Marie Florescu

853 total citations
43 papers, 367 citations indexed

About

Marie Florescu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Marie Florescu has authored 43 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 8 papers in Genetics. Recurrent topics in Marie Florescu's work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Brain Metastases and Treatment (12 papers). Marie Florescu is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Brain Metastases and Treatment (12 papers). Marie Florescu collaborates with scholars based in Canada, France and Japan. Marie Florescu's co-authors include Normand Blais, Mustapha Tehfé, Lesley Seymour, Frances A. Shepherd, Baktiar Hasan, Keyue Ding, Bertrand Routy, Denis Soulières, Xiaoduan Weng and Luis Corrales and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Marie Florescu

41 papers receiving 361 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marie Florescu Canada 12 240 188 46 45 41 43 367
R. Descourt France 13 345 1.4× 364 1.9× 19 0.4× 78 1.7× 29 0.7× 80 522
Lee Chun Park South Korea 12 95 0.4× 111 0.6× 45 1.0× 52 1.2× 43 1.0× 30 374
Sameh Daher Israel 10 155 0.6× 294 1.6× 8 0.2× 37 0.8× 23 0.6× 15 374
Jan Lemmens Belgium 6 47 0.2× 94 0.5× 45 1.0× 52 1.2× 75 1.8× 12 287
Nancy Harold United States 12 81 0.3× 360 1.9× 38 0.8× 197 4.4× 34 0.8× 27 502
N. Eche France 11 61 0.3× 113 0.6× 33 0.7× 71 1.6× 21 0.5× 25 361
Che-Kai Tsao United States 7 154 0.6× 91 0.5× 10 0.2× 84 1.9× 125 3.0× 10 338
Wataru Shioyama Japan 10 145 0.6× 89 0.5× 13 0.3× 62 1.4× 28 0.7× 36 316
Edmund Folefac United States 10 111 0.5× 133 0.7× 11 0.2× 54 1.2× 10 0.2× 36 301

Countries citing papers authored by Marie Florescu

Since Specialization
Citations

This map shows the geographic impact of Marie Florescu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Florescu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Florescu more than expected).

Fields of papers citing papers by Marie Florescu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Florescu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Florescu. The network helps show where Marie Florescu may publish in the future.

Co-authorship network of co-authors of Marie Florescu

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Florescu. A scholar is included among the top collaborators of Marie Florescu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Florescu. Marie Florescu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bélanger, Karl, Sarah Lapointe, Bernard Lemieux, et al.. (2025). A Retrospective Study on Prognostic Factors and Systemic Treatments of Refractory Meningiomas. Current Oncology. 32(9). 516–516.
2.
Alameddine, Raafat, Marie Florescu, Mustapha Tehfé, et al.. (2025). Clinical Utility of Liquid Biopsy for the Early Diagnosis of EGFR-Mutant Advanced Lung Cancer Patients in a Real-Life Setting (CLEAR Study). Current Oncology. 32(2). 57–57. 1 indexed citations
3.
Benlaïfaoui, Myriam, Julie Malo, Mélanie Drolet, et al.. (2025). Dietary compounds and patterns associated with immune checkpoint inhibitor (ICI) outcomes in advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 43(16_suppl). 2567–2567.
4.
Desîlets, Antoine, Wiam Belkaïd, Julie Malo, et al.. (2024). CRYOVATE: A Pilot Study of Lung Cancer Cryoactivation in Combination With Immunotherapy in Advanced NSCLC. JTO Clinical and Research Reports. 5(12). 100737–100737. 2 indexed citations
5.
Wong, Philip, Laura Masucci, Marie Florescu, et al.. (2023). Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases. Neuro-Oncology Advances. 5(1). vdad018–vdad018. 11 indexed citations
6.
Routy, Bertrand, Wiam Belkaïd, Danh Tran‐Thanh, et al.. (2023). The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy. Cancer Treatment and Research Communications. 37. 100767–100767. 11 indexed citations
7.
Ayoub, Jean-Pierre M., Mustapha Tehfé, Marie Florescu, et al.. (2023). Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience.. Journal of Clinical Oncology. 41(4_suppl). 86–86. 1 indexed citations
8.
Bahig, Houda, Normand Blais, Philip Wong, et al.. (2022). Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC). Clinical and Translational Radiation Oncology. 33. 115–119. 9 indexed citations
9.
Malo, J., Myriam Benlaïfaoui, Meriem Messaoudene, et al.. (2022). CN12 Impact of diet on immune checkpoint blockade: Nurse-directed dietary intervention. Annals of Oncology. 33. S1356–S1356. 1 indexed citations
10.
Bélanger, Karl, Bernard Lemieux, Jean-Paul Bahary, et al.. (2021). Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience. Current Oncology. 28(4). 3104–3114. 6 indexed citations
11.
Gaudreau, Pierre-Olivier, et al.. (2021). A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC). Cancer Treatment and Research Communications. 28. 100421–100421. 1 indexed citations
12.
Elkrief, Arielle, Corentin Richard, Julie Malo, et al.. (2020). Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France. Journal of Geriatric Oncology. 11(5). 802–806. 17 indexed citations
13.
Elkrief, Arielle, Philippe Joubert, Marie Florescu, et al.. (2020). Therapeutic Landscape of Metastatic Non-Small-Cell Lung Cancer in Canada in 2020. Current Oncology. 27(1). 52–60. 12 indexed citations
14.
Ayoub, Jean-Pierre, et al.. (2020). Prognosis in Young Women less than 40 Years of Age with Brain Metastasis from Breast Cancer. Current Oncology. 27(1). 39–45. 6 indexed citations
15.
Bélanger, K., Nathalie Letarte, Jean‐Philippe Adam, et al.. (2018). Procarbazine, Lomustine and Vincristine Toxicity in Low-Grade Gliomas. Current Oncology. 25(1). 33–39. 16 indexed citations
16.
Wong, Philip, Laura Masucci, David Roberge, et al.. (2018). MA08.11 Early Safety Data of a Phase I/II Combining Nivolumab and Stereotactic Brain Radiosurgery for Treatment of Brain Metastases in Patients with NSCLC. Journal of Thoracic Oncology. 13(10). S385–S385. 5 indexed citations
17.
Roberge, David, France Berthelet, Michel W. Bojanowski, et al.. (2017). Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report. Cureus. 9(3). e1068–e1068. 6 indexed citations
18.
Tabchi, Samer, et al.. (2017). Factors Influencing Treatment Selection and Survival in Advanced Lung Cancer. Current Oncology. 24(2). 115–122. 23 indexed citations
19.
Corrales, Luis, Denis Soulières, Xiaoduan Weng, et al.. (2013). Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study. Thrombosis Research. 133(1). 48–51. 43 indexed citations
20.
Florescu, Marie, Baktiar Hasan, Lesley Seymour, Keyue Ding, & Frances A. Shepherd. (2008). A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Thoracic Oncology. 3(6). 590–598. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Descourt Breakdown of academic impact, for papers by Lee Chun Park Breakdown of academic impact, for papers by Sameh Daher Breakdown of academic impact, for papers by Jan Lemmens Breakdown of academic impact, for papers by Nancy Harold Breakdown of academic impact, for papers by N. Eche Breakdown of academic impact, for papers by Che-Kai Tsao Breakdown of academic impact, for papers by Wataru Shioyama Breakdown of academic impact, for papers by Edmund Folefac
Rankless by CCL
2026